Skip to main content
SpringerLink
Log in

Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The development of vacuous chewing movements (VCMs), and changes in glutamic acid decarboxylase (GAD) and choline acetyltransferase (ChAT) activities in extrapyramidal nuclei were examined in rats treated chronically with neuroleptics. Animals were injected with flupenthixol (FLU) or haloperidol (HAL) decanoate for 16, 40 or 48 weeks and were then sacrificed. Another group of rats was treated with FLU or HAL for 48 weeks, and then withdrawn from the neuroleptics for 16 weeks before sacrifice. VCMs were assessed weekly, and the effects of the GABA agonist progabide on VCMs and locomotor activity were examined. GAD and ChAT activities were determined at death. The concentrations of Calbindin D28K (CaBP) and parvalbumin (PV) were determined in rats receiving 48 weeks of neuroleptic treatment. VCMs first appeared after 8–10 weeks of neuroleptic administration, reached asymptotic rates after 18–20 weeks, and then remained stable for the remainder of the chronic drug administration period. During withdrawal, there was a steady decline in the VCM rate. The GABA receptor agonist progabide reduced VCMs and locomotor activity. Significant decreases in nigral GAD activity were observed after 40, but not after either 16 or 48 weeks of neuroleptic administration. CaBP and PV were unchanged after 48 weeks of neuroleptic treatment. In addition, ChAT activities in 16, 40 or 48 week treated animals did not show consistent changes after either neuroleptic. Chronic neuroleptic administration followed by 16 weeks of withdrawal also did not have any significant effects on GAD or ChAT activity in any of the brain areas examined. The present results demonstrate that decreases in nigral GAD activity do not occur when VCMs have reached near maximal rates. It appears, therefore, that neuroleptic-induced VCMs and decreases in nigral GAD activity are not causally related. Nevertheless, the reduction in VCMs produced by progabide suggests that impaired GA-BAergic mechanisms may be involved in the expression of these abnormal perioral movements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Albers RW, Brady RO (1959) The distribution of glutamate decarboxylase in the nervous system of the rhesus monkey. J Biol Chem 234:926–928

    PubMed  CAS  Google Scholar 

  • Arnt J, Scheel-Krüger J (1980) Intranigral GABA antagonists produce dopamine-independent biting in rats. Eur J Pharmacol 62:51–61

    Article  PubMed  CAS  Google Scholar 

  • Baimbridge KG, Parkes CO, Miller JJ (1982) Calcium-binding protein distribution in the rat brain. Brain Res 239:519–525

    Article  PubMed  CAS  Google Scholar 

  • Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    Article  PubMed  CAS  Google Scholar 

  • Casey DE (1984) Tardive dyskinesia — animal models. Psychopharmacol Bull 20:376–379

    PubMed  CAS  Google Scholar 

  • Casey DE (1985) Tardive dyskinesia: reversible and irreversible. In: Casey DE, Chase TN, Christensen TR, Gerlach J (eds) Dyskinesia research and treatment. Psychopharmacology [Suppl 2]. Springer, Berlin Heidelberg New York, pp 88–97

    Google Scholar 

  • Casey DE, Gerlach J, Christensson E (1980) Dopamine, acetylcholine and GABA effects in acute dystonia in primates. Psychopharmacology 70:83–87

    Article  PubMed  CAS  Google Scholar 

  • Coward DM (1982) Nigral actions of GABA agonists are enhanced by chronic fluphenazine and differentiated by concomitant flurazepam. Psychopharmacology 76:294–298

    Article  PubMed  CAS  Google Scholar 

  • Fann WE, Lake CR, Gorber CJ, McKenzie GM (1974) Cholinergic suppression of tardive dyskinesia. Psychopharmacology 37:101–107

    Article  CAS  Google Scholar 

  • Fonnum F (1975) A rapid radiochemical method for the determination of choline acetyl transferase. J Neurochem 24:407–409

    PubMed  CAS  Google Scholar 

  • Gerfen CR, Baimbridge KG, Miller JJ (1985) The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc Natl Acad Sci USA 82:8780–8784

    Article  PubMed  CAS  Google Scholar 

  • Glassman RB, Glassman HN (1980) Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. Psychopharmacology 69:19–25

    Article  PubMed  CAS  Google Scholar 

  • Gunne L-M, Haggstrom J-E (1983) Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology 81:191–194

    Article  PubMed  CAS  Google Scholar 

  • Gunne L-M, Growdon J, Glaeser B (1982) Oral dyskinesias in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134–139

    Article  PubMed  CAS  Google Scholar 

  • Gunne L-M, Haggstrom J-E, Sjoquist B (1984) Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA-synthesis. Nature 309:347–349

    Article  PubMed  CAS  Google Scholar 

  • Haggstrom J-E, Anderson U, Gunne L-M (1981) Bromocriptine in tardive dyskinesia. Pharmacopsychiatria 15:161–163

    Article  Google Scholar 

  • Horton RW, Jenner P, Marsden CD, Prestwich SA, Rupniak NMJ (1985) Alterations in cerebral GABA parameters following treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. Br J Pharmacol 86:472P

  • Hunter WM, Greenwood FC (1962) Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194:495–496

    Article  PubMed  CAS  Google Scholar 

  • Lloyd KG, Hornykiewicz O (1977) Effect of chronic neuroleptic orl-dopa administration on GABA levels in the rat substantia nigra. Life Sci 21:1489–1496

    Article  PubMed  CAS  Google Scholar 

  • Lloyd KG, Worms P, Depoortere H, Bartholini G (1979) Pharmacological profile of SL 76002, a new GABA-mimetic drug. In: Korsgaard-Larsen P, Scheel-Krüger J, Kofod H (eds) GABA-neurotransmitters. Munksgaard, Copenhagen, pp 308–312

    Google Scholar 

  • Lowry OH, Rosebrough NJ, Farr AL, Randall AJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:259–265

    Google Scholar 

  • McGeer PL, McGeer EG, Wada JA, Jung E (1971) Effects of globus pallidus lesions and parkinson's disease on brain glutamic acid decarboxylase. Brain Res 32:425–431

    Article  PubMed  CAS  Google Scholar 

  • Mao CC, Cheney DL, Marco E, Revuelta A, Costa E (1977) Turnover times of gamma-butyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus and substantia nigra: effects of repeated administration of haloperidol. Brain Res 132:375–379

    Article  PubMed  CAS  Google Scholar 

  • Marco E, Mao CC, Revuelta A, Peralta E, Costa E (1978) Turnover rates of τ-aminobutyric acid in substantia nigra, n. caudatus, globus pallidus and n. accumbens of rats injected with cataleptogenic and noncataleptogenic antipsychotics. Neuropharmacology 17:589–596

    Article  PubMed  CAS  Google Scholar 

  • Nair NPV, Yassa R, Ruiz-Nararro J, Schwartz G (1980) Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry 135:1556–1663

    Google Scholar 

  • Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD (1983) Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined. Prog Neuro-Psychopharmacol Biol Psychiatry 7:153–164

    Article  CAS  Google Scholar 

  • Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic manipulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 79:226–230

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug associated purposeless chewing movements in rats. Psychopharmacology 85:71–79

    Article  PubMed  CAS  Google Scholar 

  • Simpson GM, Lee JH, Shrivastava RK, Branchey MH (1978) Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacol Bull 14:16–18

    PubMed  CAS  Google Scholar 

  • Stahl SM, Thornton JE, Simpson ML, Berger PA, Napoliello J (1985) Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biol Psychiatry 20:888–893

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Crayton JW, Chase TN (1979) Improvement in tardive dyskinesia after muscimol therapy. Am J Psychiatry 36:746–747

    Google Scholar 

  • Tamminga CA, Thaker GK, Ferraro TN, Hare TA (1983) GABA agonist treatment improves tardive dyskinesia. Lancet II:97–98

    Article  Google Scholar 

  • Waddington JL, Molloy AG (1987) The status of late-onset vacuous chewing/perioral movements during long-term neuroleptic treatment in rodents: tardive dyskinesia or dystonia? Psychopharmacology 91:136–137

    Article  PubMed  CAS  Google Scholar 

  • Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532

    PubMed  CAS  Google Scholar 

  • Wasserman RH (1985) Nomenclature of the Vitamin D induced calcium-binding proteins. In: Norman AW (ed) Vitamin D. de Gruyter, Berlin, pp 321–323

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurological Sciences, Department of Psychiatry, V6T 2A1, Vancouver, B.C., Canada

    S. Mithani, S. Atmadja & H. C. Fibiger

  2. Department of Physiology, University of British Columbia, V6T 2A1, Vancouver, B.C., Canada

    K. G. Baimbridge

Authors
  1. S. Mithani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Atmadja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. G. Baimbridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. C. Fibiger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mithani, S., Atmadja, S., Baimbridge, K.G. et al. Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology 93, 94–100 (1987). https://doi.org/10.1007/BF02439593

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02439593

Key words

Search

Navigation